sugemalimab
Jump to navigation
Jump to search
Indications
Dosage
- 1200 mg intravenously every 3 weeks for up to 24 months
Adverse effects
- drug adverse effects of checkpoint inhibitor(s)
- drug adverse effects of pharmaceutical monoclonal antibodies
Mechanism of action
Clinical trials
- GEMSTONE-302: sugemalimab in combination with platinum-based chemotherapy as 1st line treatment of NSCLC improves progression-free survival at 18 months relative to platinum-based chemotherapy alone[1]
More general terms
References
- ↑ 1.0 1.1 Bassett M Sugemalimab Boosts Outcomes in NSCLC. Results from two trials showed significantly prolonged PFS with the anti-PD-L1 antibody. MedPage Today January 19, 2022 https://www.medpagetoday.com/hematologyoncology/lungcancer/96754
Zhou C, Wang Z, Sun Y et al Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncology.2022 Jan 14;S1470-2045(21)00650-1 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35038432 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00650-1/fulltext